Management of risk of breast carcinoma in postmenopausal women

Biglia et al.: Breast carcinoma in postmenopausal women
Evaluation. Breast Cancer Resources and Treatment 65
125–134.
Clemons M & Goss P 2001 Estrogen and the risk of breast
cancer. New England Journal of Medicine 344 276–285.
Clemons M, Loijens L & Goss P 2000 Breast cancer risk
following irradiation for Hodgkin’s disease. Cancer Treatment
Reviews 26 291–302.
Collaborative Group on Hormonal Factors in Breast Cancer
1996a Breast cancer and hormonal contraceptives:
collaborative study of individual data on 53 297 women with
breast cancer and 100 239 women without breast cancer from
54 epidemiological studies. Lancet 347 1713–1727.
Collaborative Group on Hormonal Factors in Breast Cancer
1996b Breast cancer and hormonal contraceptives: further
results. Contraception 54 (Suppl. 3) 1–106.
Collaborative Group on Hormonal Factors in Breast Cancer
1997 Breast cancer and hormone replacement therapy:
collaborative reanalysis of data from 51 epidemiological
studies of 52 705 women with breast cancer and 10 8411
women without breast cancer. Lancet 350 1047–1059.
Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ,
Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow
M et al. 1999 The effect of raloxifene on the risk of breast
cancer on postmenopausal women: results from the MORE
randomized trial. Journal of the American Medical Association
281 2189–2197.
Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M &
Krueger KA 2002 Serum estradiol level and risk of breast
cancer during treatment with raloxifene. Journal of the
American Medical Association 287 216–220.
Cuzick J 2001 A brief review of the International Breast Cancer
Intervention Study (IBIS), the other current breast cancer
prevention trials, and proposals for future trials. Annals of
New York Academy of Sciences 949 122–133.
Dirx MJ, Voorrips LE, Goldbohm RA & Van Der Brandt PA
2001 Baseline recreational physical activity, history of sports
participation, and postmenopausal breast carcinoma risk in
the Netherlands Cohort Study. Cancer 92 1638–1649.
Dupont WD & Page DL 1985 Risk factors for breast cancer in
women with proliferative breast disease. New England Journal
of Medicine 312 146–151.
Easton DF, Bishop DT, Ford D & Crockford GP 1993 Genetic
linkage analysis in familial breast and ovarian cancer: results
from 214 families. American Journal of Human Genetics 52
678–701.
Egan KM, Stampfer MJ, Hunter D, Hankinson S, Rosner BA,
Holmes M, Willet WC & Colditz GA 2002 Active and passive
smoking in breast cancer: prospective results from the Nurses’
Health Study. Epidemiology 13 138–145.
Ettinger B, Black DM, Mitlak BH, Knickerbocker RK,
Nickelsen T, Genant HK, Christiansen C, Delmas PD,
Zanchetta JR, Stakkestad J et al. 1999 Reduction of vertebral
fracture risk in postmenopausal women with osteoporosis
treated with raloxifene: results from a 3-year randomized
clinical trial. Multiple Outcomes of Raloxifene Evaluation
(MORE) Investigators. Journal of the American Medical
Association 282 637–645.
Fisher B, Costantino JP, Wickerham DL, Redmond CK,
Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov
N, Atkins J et al. 1998 Tamoxifen for prevention of breast
cancer: report of the National Surgical Adjuvant Breast and
Bowel Project P-1 Study. Journal of the National Cancer
Institute 90 1371–1388.
Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM,
Tartter PI, Brower ST & Eng CM 1998 Frequency and carrier
risk associated with common BRCA 1 and BRCA 2
mutations in Ashkenazi Jewish breast cancer patients.
American Journal of Human Genetics 63 45–51.
Fowble B, Hanlon A, Freedman G, Patchefsky A, Kessler H,
Nicolaou N, Hoffman J, Sigurdson E, Boraas M & Goldstein
L 1999 Postmenopausal hormone replacement therapy: Effect
on diagnosis and outcome in early-stage invasive breast
cancer treated with conservative surgery and radiation.
Journal of Clinical Oncology 17 1680–1688.
Friedenreich CM 2001 Review of anthropometric factors and
breast cancer risk. European Journal of Cancer Prevention 10
15–32.
Friedenreich CM, Courneya KS & Bryant HE 2001 Influence of
physical activity in different age and life periods on the risk of
breast cancer. Epidemiology 12 604–612.
Gambrell RD Jr 1996 Hormone replacement therapy and breast
cancer risk. Archives of Family Medicine 5 341–348.
Gapstur SM, Morrow M & Sellers TA 1999 Hormone
replacement therapy and risk of breast cancer with a
favorable histology: results of the Iowa Women’s Heatlth
Study. Journal of the American Medical Association 281
2091–2097.
Ginsburg ES 1999 Estrogen, alcohol, and breast cancer risk.
Journal of Steroid Biochemistry and Molecular Biology 69
299–306.
Grabrick DM, Hartmann LC, Cerhan JR, Vierkant RA,
Therneau TM, Vachon CM, Olson JE, Couch FJ, Anderson
KE, Pankratz VS & Sellers TA 2000 Risk of breast cancer
with oral contraceptive use in women with a family history of
breast cancer. Journal of the American Medical Association
284 1791–1798.
Grann VR, Jacobson JS, Whang W, Hershman D, Heitjan DF,
Antman KH & Neugut AI 2000 Prevention with tamoxifen or
other hormones versus prophylactic surgery in BRCA1/2
positive women: a decision analysis. Cancer Journal from
Scientific American 6 13–20.
Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE,
Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ,
Hennekens CH & Speitzer FE 1997 Postmenopausal hormone
therapy and mortality. New England Journal of Medicine 336
1769–1775.
Heimdal K, Skovlund E & Moller P 2002 Oral contraceptives and
risk of familial breast cancer. Cancer Detection and Prevention
26 23–27.
Henderson BE, Paganini-Hill A & Ross RK 1991 Decreased
mortality in users of estrogen replacement therapy. Archives
of Internal Medicine 151 75–78.
Hildreth NG, Shore RE & Dvoretsky PM 1989 The risk of breast
cancer after irradiation of the thymus in infancy. New England
Journal of Medicine 321 1281–1284.
Horn-Ross PL, John EM, Lee M, Stewart SL, Koo J, Sakoda
LC, Shiau AC, Goldstein J , Davis P & Perez-Stable EJ 2001
Phytoestrogen consumption and breast cancer risk in a
80 www.endocrinology.org